Preprint Review Version 2 Preserved in Portico This version is not peer-reviewed

Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents

Version 1 : Received: 12 October 2019 / Approved: 13 October 2019 / Online: 13 October 2019 (15:22:27 CEST)
Version 2 : Received: 7 November 2019 / Approved: 7 November 2019 / Online: 7 November 2019 (14:59:43 CET)
Version 3 : Received: 26 December 2019 / Approved: 27 December 2019 / Online: 27 December 2019 (03:35:32 CET)
Version 4 : Received: 27 January 2020 / Approved: 27 January 2020 / Online: 27 January 2020 (02:09:09 CET)
Version 5 : Received: 7 February 2020 / Approved: 10 February 2020 / Online: 10 February 2020 (09:55:44 CET)
Version 6 : Received: 12 February 2020 / Approved: 14 February 2020 / Online: 14 February 2020 (02:27:24 CET)

How to cite: Andersen, P.I.; Ianevski, A.; Lysvand, H.; Vitkauskiene, A.; Oksenych, V.; Bjoras, M.; Telling, K.; Lutsar, I.; Dumpis, U.; Irie, Y.; Tenson, T.; Kantele, A.; Kainov, D.E. Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents. Preprints 2019, 2019100144. https://doi.org/10.20944/preprints201910.0144.v2 Andersen, P.I.; Ianevski, A.; Lysvand, H.; Vitkauskiene, A.; Oksenych, V.; Bjoras, M.; Telling, K.; Lutsar, I.; Dumpis, U.; Irie, Y.; Tenson, T.; Kantele, A.; Kainov, D.E. Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents. Preprints 2019, 2019100144. https://doi.org/10.20944/preprints201910.0144.v2

Abstract

Viral diseases are one of the leading causes of morbidity and mortality in the world. Broad-spectrum antiviral agents (BSAAs) are key players in control of human viral diseases. Here, we reviewed the discovery and development process of BSAAs, focusing on compounds with available safety profiles in human. In addition, we summarized the information on approved, investigational and experimental safe-in-man BSAAs in freely accessible database at https://drugvirus.info/. The number of approved BSAAs will be increased as well as their spectrum of indications will be expanded pending the results of further pre-clinical and clinical studies. This will ultimately reinforce the arsenal of available antiviral options and provide better protection of general population from emerging and re-emerging viral diseases.

Keywords

virus; antiviral drug; drug discovery; drug development; broad-spectrum antivirals

Subject

Biology and Life Sciences, Virology

Comments (1)

Comment 1
Received: 7 November 2019
Commenter: Denis Kainov
Commenter's Conflict of Interests: Author
Comment: Updated version - text was modified according to reviewers comments
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.